Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02636972




Registration number
NCT02636972
Ethics application status
Date submitted
6/12/2015
Date registered
22/12/2015

Titles & IDs
Public title
The Progression From Dysmenorrhoea to Chronic Pelvic Pain
Scientific title
The Progression From Dysmenorrhoea to Chronic Pelvic Pain: Investigation of the Role of Chronic Inflammatory Pain Phenotype in Peripheral Blood as a Potential Biomarker.
Secondary ID [1] 0 0
PPAI-001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Dysmenorrhoea 0 0
Pelvic Pain 0 0
Chronic Pain 0 0
Condition category
Condition code
Neurological 0 0 0 0
Other neurological disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Reproductive Health and Childbirth 0 0 0 0
Menstruation and menopause

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Treatment: Drugs - OCPs

Group 1 - Mild or absent dysmenorrhoea and no other pelvic pain symptoms without contraceptive pill use.

Group 2A - History of mild or absent dysmenorrhoea prior to pill use and no other pelvic pain symptoms with contraceptive pill use (Participants already using contraceptive pills).

Group 2B - History of severe dysmenorrhoea prior to pill use and no other pelvic pain symptoms with contraceptive pill use (Participants already using contraceptive pills).

Group 3 - Severe dysmenorrhoea but without chronic pelvic pain and without contraceptive pill use.

Group 4 - Severe dysmenorrhoea but without chronic pelvic pain and with contraceptive pill use (Participants already using contraceptive pills).

Group 5 - Chronic pelvic pain and severe dysmenorrhoea without contraceptive pill use

Group 6 - Chronic pelvic pain and severe dysmenorrhoea with contraceptive pill use (Participants already using contraceptive pills).


Treatment: Drugs: OCPs
Participants in the contraceptive pill groups can use any one of the following contraceptive pills:

Oestradiol valerate and dienogest, drospirenone and ethinyl estradiol , ethinyloestradiol and levonorgestrel, cyproterone and ethinyl estradiol, ethinylestradiol and norethisterone, Nomegestrol Acetate and Oestradiol and Ethinyl Estra
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Reactivity of stimulated isolated peripheral blood immune cells
Timepoint [1] 0 0
2 weeks
Secondary outcome [1] 0 0
Impact of pelvic pain on everyday activities using the Pelvic Pain Questionnaire
Timepoint [1] 0 0
2 weeks
Secondary outcome [2] 0 0
Levels of anxiety and depression using the DAS21
Timepoint [2] 0 0
2 weeks

Eligibility
Key inclusion criteria
* Age between 16 to 35 years old
Minimum age
16 Years
Maximum age
35 Years
Sex
Females
Can healthy volunteers participate?
Yes
Key exclusion criteria
* Irregular menstrual cycles
* Use of any reproductive hormonal preparations (other than the combined oral contraceptive pill), thyroxine, insulin or corticosteroids
* Presence of an inflammatory process, or clinically significant infection in the 4 weeks
* Clinically significant renal, hepatic, cardiac, auto-immune disease
* Current use of immunosuppressant medication such as hydroxychloroquine, methotrexate or azathioprine
* Inability to read or comprehend the written information provided
* Current use of medications known to affect TLR responsiveness including amitriptyline or minocycline
* Current use of any analgesics, including non-steroidal anti-inflammatory medications and opioids for 5 drug half-lives prior to the day of testing
* Current or previous pregnancy
* Body Mass index less than 18 or more than 30

Study design
Purpose
Duration
Selection
Timing
Statistical methods / analysis

Recruitment
Recruitment status
UNKNOWN
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/11/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/01/2016
Actual
Sample size
Target
56
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
PARC, Royal Adelaide Hospital - Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Other
Name
University of Adelaide
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Susan Evans, MBBS
Address 0 0
PARC Research Clinic
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT02636972